Paysign price target raised to $7.25 from $6 at Ladenburg

Ladenburg raised the firm’s price target on Paysign to $7.25 from $6 and keeps a Buy rating on the shares. Strong Q2 results and management’s comments concerning traffic patterns and the potential for increasing numbers of new Pharma programs point to continued solid revenue gains through 2025, according to the analyst, who believes that “it is clear that the Pharma segment is now the primary driver of revenue growth.”